Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
For quite a while now, the perception of the STEM
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceuticals Limited (Alembic) today an
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
The first nasal vaccine against COVID-19, developed by Bharat Biotech, has received regulator’s nod for conducting phase 2 and 3 clinical trials, the Department of Biotechnology said on Friday.
Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said.
This is the first of its kind COVID-19 jab to undergo human clinical trials in India.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.
